In recent trading, shares of Becton, Dickinson & Co (Symbol: BDX) have crossed above the average analyst 12-month target price of $200.40, changing hands for $200.43/share. When a stock reaches the ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Becton, Dickinson and Company has lagged behind the broader market over the past year, yet analysts remain somewhat optimistic about the stock’s prospects.

If you are wondering whether Becton Dickinson is starting to look like good value, you are not alone. This article will help you frame that question clearly. The stock last closed at US$177.38, with a ...

Shares of Becton Dickinson and Company (NYSE:BDX) are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting ...

Fintel reports that on May 1, 2025, William Blair downgraded their outlook for Becton, Dickinson and (NYSE:BDX) from Outperform to Market Perform. Analyst Price Forecast Suggests 33.00% Upside As of ...

In the latest quarter, 7 analysts provided ratings for Becton Dickinson (NYSE:BDX), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -5.78% in the ...

Becton, Dickinson and Company is rated a hold due to low growth, valuation concerns, and underperformance compared to healthcare equipment peers. BDX's acquisition of Edwards Lifesciences’ Critical ...